HiLand Launches Exosome Process Development Program to Advance Next-Generation Therapeutics
March 10, 2025 – San Francisco, USA
HiLand today announced the official launch of its exosome process development program, establishing industrial-level capabilities for exosome production, purification, and assay development. This initiative is designed to support drug developers and researchers seeking to harness the unique potential of exosomes in addressing unmet medical needs where conventional therapeutic approaches have proven insufficient.
Exosomes are nanosized extracellular vesicles naturally secreted by cells, functioning as mediators of intercellular communication by transferring proteins, nucleic acids, and lipids between cells. Their unique biological properties have attracted widespread interest as novel therapeutic and diagnostic tools. Applications under exploration include targeted drug delivery, regenerative medicine, immune modulation, and oncology, as well as their use as biomarkers for disease diagnosis and monitoring.
With its dedicated team of experts, HiLand has successfully developed robust, scalable processes for exosome production, advanced purification platforms to ensure safety and consistency, and sensitive analytical assays to characterize and validate exosome-based products. These capabilities are designed to accelerate translation from discovery research to clinical development and eventual commercial production.
HiLand warmly welcomes researchers and pharmaceutical developers to collaborate on this exciting frontier in medicine. By combining deep expertise in biologics development with cutting-edge exosome technologies, HiLand aims to empower partners to pioneer new therapies that can address critical unmet clinical needs and bring transformative benefits to patients worldwide.
Histol Histopathol. 2025 Mar 12:18903. doi: 10.14670/HH-18-903.
